‘Hepatitis is a silent threat that affects all age groups'
On July 28, observed as World Hepatitis Day, doctors in Hyderabad have raised an alarm on the growing burden of liver disease in India, and have called for urgent awareness, early screening, and preventive action.
Hepatitis, which refers to inflammation of the liver, can be caused by a wide range of factors, including viral infections, alcohol consumption, unhealthy diet, obesity, and even certain medications. In India alone, over 40 million people are living with Hepatitis B, and up to 12 million with Hepatitis C, most of them unaware of the problem. The virus often stays dormant for years, silently damaging the liver, and only revealing itself when the damage is severe, said Kavya Dendukuri, Lead Transplant Hepatologist at Gleneagles Hospital.
She further added that hepatitis is not a single disease. It includes types, A, B, C, D, and E, each with its own causes and modes of transmission. Hepatitis A and E spread through contaminated food and water, while B and C are transmitted through infected blood, unprotected sex, shared needles, or from mother to child. Hepatitis D occurs only in those already infected with B.
'Earlier, hepatitis was largely seen in the elderly due to alcohol or long-standing infections. Now, we are seeing non-alcoholic fatty liver disease in people as young as 40 due to sedentary lifestyles, poor diets, and obesity.' said V.R. Sumanth Kumar and Tejaswini Tumma, Consultant Gastroenterologists at Kamineni Hospitals.
Auto-immune hepatitis, drug-induced hepatitis, and alcohol-related liver inflammation are also on the rise.
'Many people don't realise that certain herbal medicines, painkillers, or even overdosing on paracetamol can trigger serious liver inflammation,' warnedSrinivasa Reddy G from Star Hospitals.
One of the greatest challenges in tackling hepatitis is that most people show no symptoms until the disease is advanced. Common signs, when they do appear include fatigue, nausea, abdominal pain, loss of appetite, dark urine, pale stools, and jaundice. But by then, the liver may already be scarred.
Akash Chaudhary from CARE Hospitals shared that hepatitis is preventable and, in many cases, curable. Vaccines are available for Hepatitis A and B, and all new-borns and high-risk adults should receive them.
'Treatments for Hepatitis C, once considered expensive and complex, now involves short-term oral medication with near-total cure rates. Hepatitis B can be managed through daily anti-viral tablets, which have become highly affordable,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
a day ago
- Hindustan Times
Health Talk: Taking the road to hepatitis elimination
The International Agency for Research on Cancer (IARC) recently classified hepatitis D as carcinogenic—cancer-causing—to humans, just like hepatitis B and C. Hepatitis D, which only affects individuals infected with hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone, it added. (AP/ Representative photo) Hepatitis D, which only affects individuals infected with hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone, it added. Viral hepatitis – types A, B, C, D, and E – are major causes of acute liver infection. Among these, only hepatitis B, C, and D can lead to chronic infections that significantly increase the risk of cirrhosis, liver failure, or liver cancer. Each year, July 28 is observed as World Hepatitis Day, as viral hepatitis continues to remain a serious public health threat and one of the primary causes of liver cancer. Yet most people with hepatitis don't know they're infected, says the World Health Organization (WHO). According to the UN health body, types B, C, and D affect at least 300 million people globally and cause at least 1.3 million deaths each year, mainly from liver cirrhosis and cancer. In a paper published on Monday, The Lancet Commission also mentioned that three in five liver cancer cases happen due to preventable risk factors, including fatty liver, alcohol, and viral hepatitis. It also added that obesity-linked cancer cases are on the rise. The majority of liver cancer cases can be prevented by reducing levels of viral hepatitis, alcohol consumption, and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), it said. Liver cancer is already a major cause of death and disability. Globally, it's the sixth most common cancer and the third leading cause of death from cancer. Interestingly, the Commission estimated in the paper that at least 60% of liver cancers are preventable via control of modifiable risk factors, including hepatitis B virus (HBV), hepatitis C virus (HCV), MASLD, and alcohol. While there are preventive measures and treatment available to combat this public health threat, last year's Global Hepatitis Report underscored some challenges that majorly impact disease management. According to the report, testing and treatment coverage remain critically low: only 13% of people with hepatitis B and 36% with hepatitis C had been diagnosed by 2022. Treatment rates were even lower – 3% for hepatitis B and 20% for hepatitis C – well below the 2025 targets of 60% diagnosed and 50% treated. Integration of hepatitis services remained uneven: 80 countries have incorporated hepatitis services into primary health care, 128 into HIV programmes, and just 27 have integrated hepatitis C services into harm reduction centres. The next challenge, according to the report, will be to scale up the implementation of prevention, testing, and treatment coverage. Achieving WHO's 2030 targets could save 2.8 million lives and prevent 9.8 million new infections. With declining donor support, countries must prioritize domestic investment, integrated services, better data, affordable medicines, and ending stigma, said experts in the report. 'Every 30 seconds, someone dies from a hepatitis-related severe liver disease or liver cancer. Yet we have the tools to stop hepatitis,' WHO director-general Tedros Adhanom Ghebreyesus said in a statement on World Hepatitis Day. He is right. We have the tools at our disposal; all we need is for stakeholders—governments, civil society, community leaders, etc.—to come together, to jointly work towards eliminating hepatitis.
The Print
2 days ago
- The Print
All about hepatitis D, deadly viral hepatitis given a ‘cancer' tag by WHO
Hepatitis D or HDV, which only affects individuals infected with hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone, according to the IARC. Viral hepatitis, characterised by inflammation of the liver, can be caused by the five known hepatitis viruses—A, B, C, D and E. Among these, only hepatitis B, C, and D can lead to chronic infections that significantly increase the risk of cirrhosis, liver failure, or liver cancer. New Delhi: The World Health Organisation-International Agency for Research in Cancer (WHO-IARC) has now declared hepatitis D, a little-known but deadly viral hepatitis, as carcinogenic, expressing hope that this will lead to more screening and access to new treatments. It is estimated that globally, 48 million people are affected with HDV, which in combination with the hepatitis B virus, has the highest fatality rate of all the hepatitis infections, at 20 percent. Its prevalence is highest in low- and middle-income regions in Africa and Asia, apart from the Amazon basin and India. Scientific evidence has shown that 8-37 percent, depending on the region, of those infected with hepatitis B, also have HDV. A 2024 report by the WHO had said that India had over 3.5 crore cases of viral hepatitis—including 2.98 crore hepatitis B cases—in 2022, accounting for 11.6 percent of the total disease burden globally that year. Over 1.25 lakh people, the report suggested, had died due to hepatitis B and C in India that year. Senior gastroenterologists and public health professionals suggested that HDV is largely undetected in the country, mainly because of lack of screening, and is more prevalent in some parts of east India and among people infected with HBV. 'From a public health perspective, this classification by WHO-IARC highlights the importance of incorporating HDV awareness, screening, and prevention into the existing hepatitis B prevention programme,' Dr Saswata Chatterjee, gastroenterologist with the Calcutta Medical Research Institute (CMRI), told ThePrint. With liver cancer becoming a challenging burden, screening and early detection of co-infections, such as HDV, will be crucial in reducing chronic complications of viral hepatitis, he added. Also Read: Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits HBV triggers rapid progression to end-stage liver failure Dr Piyush Ranjan, senior gastroenterologist with Sir Ganga Ram Hospital in Delhi, explained that HDV is a satellite virus that requires hepatitis B virus (HBV) for replication, causing the most aggressive form of viral hepatitis. Compared to hepatitis B and C, HDV leads to more rapid progression to cirrhosis and liver cancer. In clinical terms, explained CMRI's Dr Chatterjee, HDV occurs as a co-infection—when it is contracted simultaneously with HBV—or a superinfection—when an individual who is chronically infected with HBV becomes infected with HDV. While HBV increases the risk of developing liver complications, HDV increases this risk substantially, accelerating the progression of liver fibrosis, cirrhosis and malignancy. The mode of transmission of this hepatitis virus is similar to hepatitis B and C—through contaminated injections, mother to child, and sexual contact. Dr Vibhor Sharma, a medical oncologist with Asian Hospital, highlighted that co-dependency of HDV on HBV leads to making hepatitis worse in patients. 'HDV-triggered liver disease is more severe as it can result in end-stage liver failure in less than ten years,' he said, adding that as compared to the general population in India, this form of hepatitis is seen more commonly in intravenous drug users, HIV/AIDS patients and those with chronic HBV. The declaration by the WHO-IARC is crucial, said the medical oncologist as HDV, despite its aggressiveness in triggering liver cancers, is mostly undiagnosed and is grossly underreported in developing countries such as India. Prevention and management Clinicians say HDV is preventable at a low cost, through immunisation. The effective methods to prevent both HBV and HDV are the vaccines against hepatitis B, safe blood practices, sterilisation of medical equipment, and safe sex practices, said Dr Chatterjee. The HBV vaccine in India, as part of the Union government 's Universal Immunization Programme, was piloted in 2002-03 and then scaled up in the entire country in 2010 to protect children from the acute infection. It is now provided as part of the pentavalent vaccine at 6, 10 & 14 weeks apart from the birth dose of hepatitis B vaccine. However, a 2020 study from India said that although the coverage of third-dose hepatitis B vaccine has reached 86 percent in the country, the birth dose coverage was under 50 percent in 2015 despite high rates of institutional deliveries. The WHO says that while treatment with oral medicine can cure hepatitis C within 2 to 3 months and effectively suppress hepatitis B with life-long therapy, treatment options for hepatitis D are evolving. Sir Ganga Ram's Dr Ranjan maintained that for those already infected, management is challenging, with limited approved therapies, though newer agents like bulevirtide—an antiviral therapy especially developed against the condition—offer promise. 'The carcinogen tag will hopefully intensify global surveillance, funding, and research to curb the burden of HDV-associated liver cancer,' said the gastroenterologist. (Edited by Gitanjali Das) Also Read: Cancer warning on liquor bottles 'long overdue'. Even 'light', 'moderate' drinking poses threat
Business Standard
3 days ago
- Business Standard
STAR Hospitals and MyGate Collaborate to Deliver Community-Based Multispecialty Healthcare in Hyderabad
VMPL Hyderabad (Telangana) [India], August 1: In a pioneering move set to redefine healthcare access in India, STAR Hospitals, Hyderabad's premier healthcare provider, has partnered with MyGate, India's leading community management platform, to launch 'STAR Services on MyGate'. This landmark initiative was officially launched on 30th July 2025 at 12:30 PM at Pramana Hall, STAR Hospitals, Nanakramguda, followed by lunch. This first-of-its-kind initiative brings advanced medical services directly to gated communities through the MyGate platform, empowering residents with tech-enabled, on-demand access to quality Multispecialty services. The launch event was graced by distinguished dignitaries: Shri D. Sridhar Babu, Hon'ble Minister of Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana, who served as Chief Guest. * Shri Arekapudi Gandhi, Hon'ble MLA of Serilingampally, as Guest of Honour. * Shri Rohit Jindal, Co-Founder & CBO of MyGate, as Special Guest. They were joined by STAR Hospital's leadership. * Dr. Gopichand Mannam (Managing Director) * Dr. Ramesh Gudapati (Joint Managing Director). * Dr. Rahul Medakkar (Chief Executive Officer) reiterated STAR's mission to make world-class healthcare more accessible and community-centric. Transforming Access to Healthcare Right at Your Doorstep This landmark collaboration integrates STAR's clinical excellence across 30+ specialties with MyGate's hyper-local reach across 1,800+ residential communities and over 5 lakh families in Hyderabad. For the first time in India, a hospital group and community mobile application platform are working together to proactively deliver healthcare in everyday life, not just in emergencies. Residents will now have access to: 1. Seamless specialist doctor appointments 2. Preventive health & early detection advisories 3. Information on specialty-specific hospital services 4. Emergency response protocols & first-response guidelines 5. Basic Life Support (BLS) awareness & training sessions From Vision to Action: Leader Insights Driving India's Community Health Renaissance "Before I speak as a Minister, let me speak as a citizen, one who has seen both the awe and the agony in the eyes of patients waiting for care. Healthcare is not just a sector; it is the soul of society. Today, in a city emerging as India's medical capital, we launch a first-of-its-kind partnership -- STAR Services on MyGate. For the first time, a hospital and a community-tech platform have come together to turn gated communities into health-aware zones. We are bringing specialist access, emergency readiness, and BLS awareness directly to the doorstep, where care begins before crisis strikes. The need is urgent. 5.2 million Indians die annually from treatable conditions, and 70% of urban emergencies are delayed due to lack of trained first responders. Telangana has contributed over 2.23 crore consultations to eSanjeevani. Yet, 60% of chronic conditions remain undiagnosed. While 80% of advanced diagnostics are limited to metros, the demand is growing -- home-based diagnostics are projected to cross $8.6 billion by 2027. This initiative is not just timely -- it's transformative. And for doctors, it brings support systems built on meaningful data, not to replace their intuition, but to reinforce it. This is the future Telangana envisions. With AI-enabled screenings, Digital Health Cards, and TGDeX for secure health data exchange, we're building a healthcare model rooted in both innovation and dignity. Our goal is clear: to contribute 10% to India's projected $30 billion digital health economy. But more than economic growth, we are investing in lives. From digital to dignity, from data to doorstep. Telangana is ready to lead India's Tech-Integrated Healthcare Renaissance."-Shri D. Sridhar Babu, Hon'ble Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana. "Community-first healthcare is no longer an aspiration, it's a necessity. This initiative ensures that residents across Serilingampally and beyond are more prepared, informed, and supported in their daily health journeys." - Shri Arekapudi Gandhi, Hon'ble MLA, Serilingampally. "At MyGate, we aim to empower communities with everyday solutions that matter healthcare being among the most essential. Our partnership with STAR Multispecialty Hospitals ensures that health becomes an integrated part of community living, not just an emergency response." - Shri Rohit Jindal, Co-Founder & CBO, MyGate. A New Chapter in Community Health: This collaboration reflects a shared commitment to building healthier, more connected neighborhoods through innovation. Community leaders, insurers, and civic stakeholders at the event welcomed this model as a scalable blueprint for future-ready urban health ecosystems. "STAR Hospitals has always led from the front whether in advanced specialties or now in reimagining community access. With MyGate, we're embedding healthcare where it belongs: into people's everyday lives." - Dr. Gopichand Mannam, Managing Director, STAR Hospitals "The future of healthcare lies in prevention and proximity. This partnership enables us to place life-saving information and care into the hands of residents before a crisis hits." - Dr. Ramesh Gudapati, Joint Managing Director, STAR Hospitals "This initiative is more than a service extension; it's a strategic leap towards anticipating healthcare needs, enhancing public health, and transforming urban wellness." - Dr. Rahul Medakkar, Chief Executive Officer, STAR Hospitals With 'STAR Services on MyGate', healthcare becomes more than just a visit to the hospital, it becomes a way of life. This first-of-its-kind partnership signals a new era in Indian healthcare where technology, community, and clinical excellence come together to ensure healthier futures for all.
